National Health Act 1953 - Determination under subsection 85B(1) (No. PB 5 of 2007)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, addresses the need for a structured and reliable system to provide access to necessary and cost-effective medicines. The Act, specifically through Part VII, regulates the Australian Pharmaceutical Benefits Scheme (PBS), which ensures the timely and affordable availability of essential drugs and medicinal preparations. The purpose of the PBS, as stated, is to guarantee that Australians can access necessary medications in a reliable and affordable manner. The Act empowers the Minister to determine the prices for pharmaceutical benefits, ensuring that the government subsidy aligns with the manufacturer's requirements. This regulatory framework was established to facilitate the inclusion of drugs on the PBS, based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC), an independent expert body tasked with assessing the clinical effectiveness, safety, and cost-effectiveness of medicines. The PBAC's recommendations are crucial in determining which drugs are listed on the PBS, thereby ensuring that the scheme operates efficiently and effectively to meet the health needs of the community.

Scope and Application

The National Health Act 1953, through its Part VII, governs the Australian Pharmaceutical Benefits Scheme (PBS) which ensures affordable access to necessary and cost-effective medicines for the Australian community. This determination under subsection 85B(1) of the Act applies to pharmaceutical benefits where there is a price difference between what the Government is prepared to subsidise and the price required by the manufacturer. This includes determining the reimbursement price to the pharmacist and the manufacturer’s requested price for specific drugs and medicinal preparations. The Pharmaceutical Benefits Advisory Committee (PBAC), established under the Act, recommends drugs and preparations to be included in the PBS, considering their clinical effectiveness, safety, and cost-effectiveness. This determination, effective from 1 January 2007, amends the Principal Determination by changing the drug description for Bleomycin Sulfate to include the required solvent, Sodium Chloride injection 10 mL, reflecting its relisting as an approved solvent. The amendment is detailed in the attached schedule, which lists the affected pharmaceutical benefits, their forms, brands, pack sizes, and the relevant prices.

Key Provisions

The main operative sections of this determination under subsection 85B(1) of the National Health Act 1953 pertain to the regulation of the Australian Pharmaceutical Benefits Scheme (PBS), particularly in relation to the supply of listed drugs and medicinal preparations as pharmaceutical benefits (section 85). Subsection 85B(1) empowers the Minister to determine the price differences between the government's subsidy and the manufacturer's required price for certain pharmaceutical benefits, including those under special patient contribution items, the therapeutic group premium policy, and the brand premium policy. This determination specifically amends the Schedule to the Principal Determination, made on 7 November 2006, by updating the drug and form description for Bleomycin Sulfate to include Sodium Chloride injection 10 mL as an approved solvent when the injectable forms are prescribed with a solvent, effective from 1 January 2007. The obligations and requirements imposed by this Act on the parties involved include adherence to the pricing determinations set out in the Schedule. This involves ensuring that the prices listed for each pharmaceutical benefit reflect the negotiated terms between the government and the manufacturers. Additionally, the Pharmaceutical Benefits Advisory Committee (PBAC), established under section 100A of the Act, plays a critical role by recommending which drugs and medicinal preparations should be available as pharmaceutical benefits. For a drug or medicinal preparation to be declared under Part VII of the Act, it must first be recommended by the PBAC, which considers the medical conditions for which the medicine has been approved, its clinical effectiveness, safety, and cost-effectiveness relative to other treatments. The PBAC comprises members from various relevant fields, including consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists, and specialists, ensuring a broad and expert perspective on recommendations. The determination outlines specific civil and criminal consequences for breaches of the provisions set out in the Act. While the explanatory statement does not explicitly state the maximum penalties for violations, it is understood that non-compliance with the Act's requirements could result in legal actions, including fines and other administrative penalties. The PBS aims to provide affordable access to necessary and cost-effective medicines, and any failure to adhere to the stipulated prices or other requirements could disrupt this objective, potentially leading to legal repercussions for the offending parties. The precise penalties for breaches are likely detailed in other sections of the Act or related legislative instruments, but the overarching aim is to maintain the integrity and functionality of the PBS.